Core Insights - The global position of China's pharmaceutical innovation industry has significantly improved, which is expected to drive a comprehensive recovery across the entire industry chain [1][7] - The non-ferrous metals industry is anticipated to maintain high prosperity due to multiple favorable factors [1][7] - The AI industry is entering a critical phase of synergy between computing power and applications, transitioning from concept speculation to performance realization [1][7] Industry Analysis - In the fourth quarter of 2025, structural opportunities are expected to continue to emerge, with non-ferrous metals, chemicals, AI applications, military industry, innovative pharmaceuticals, and new consumption sectors leading in market performance [4][11] - The pharmaceutical industry is predicted to have reached a turning point, with innovative drugs being the core focus of the current rebound, showing strong performance throughout the year [4][11] - The non-ferrous metals sector is experiencing an upward trend driven by improved supply-demand dynamics, policy support, and new demand growth, indicating sustained high prosperity [11] - The AI sector is witnessing a shift from speculative investment to performance-driven growth, with both AI computing power and application segments achieving rapid expansion [5][11] Investment Strategy - Investment strategies should focus on leading companies with clear upward trends in copper prices and explore structural opportunities in rare metals such as aluminum, rare earths, and lithium, driven by new energy and AI data center scenarios [5][11] - The management of the fund will continue to track industry trends, seize core opportunities, and optimize portfolio configurations to aim for long-term stable returns for investors [5][11]